在接受生物标志物导向治疗分子测试的癌症患者中的健康差异
Elisabeth Heath1, Gregory Dyson1, Jennifer R Ribeiro2
1Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Cancer research communications
|August 22, 2024
概括
癌症患者的分子测试显示,结果中的种族差异减少了. 然而,持续的差异受到年龄和性别的影响,特别是在特定的瘤类型中.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 健康差距 研究 研究 研究 研究
背景情况:
- 健康差异显著阻碍了成功的癌症治疗结果.
- 精确瘤学在缓解这些差异方面的作用仍然未得到充分探索.
研究的目的:
- 分析分子测试对瘤学健康差异的影响.
- 研究基因组特征,患者人口统计和整体存活率之间的关系.
主要方法:
- 对来自六个癌症中心 (2010-2020) 的12627名患者进行了回顾性分析,并进行了分子瘤测试.
- 卡普兰-梅尔和考克斯回归用于整体生存分析.
- 基平方和ANOVA测试用于分子和人口特征分析.
主要成果:
- 接受分子测试的患者表现出基于种族,地点或贫困的结果差异很小.
- 种族差异主要观察到测试队列中的年轻非白人女性,以及更广泛地在一般人群中.
- 在APC,EGFR,STK11,TP53和KRAS的突变影响了生存率,在某些瘤类型中具有种族特异性流行率.
结论:
- 分子测试与与普通人群相比,癌症患者的种族健康差异减少有关.
- 年龄和性别显著影响持续的种族差异,需要针对瘤血统进行特定的检查.
- 扩大对分子检测的准入可能会提高健康公平性,并改善所有患者的癌症结果.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.8K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
